Anti-cancer agents in medicinal chemistry · 2026
Euxanthone Inhibits Hepatocellular Carcinoma Progression by Targeting the miR-199a-5p/E2F3 Regulatory Axis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al Awadh Ahmed Abdullah
Аннотация
INTRODUCTION: Hepatocellular carcinoma (HCC) ranks among the leading causes of cancer-related deaths on a global scale. This study aimed to evaluate the effects of euxanthone on the proliferation of HCC cell lines and elucidate the underlying molecular mechanisms.
METHODS: HCC cell lines (HepG2, Huh-7, SNU-398, SK-HEP-1, Hep3B) and the normal liver cell line THLE-2 were cultured and treated with euxanthone at concentrations between 0 and 100 μM. Cell viability was evaluated using the MTT assay, while phase contrast microscopy and cell cycle analysis were performed to evaluate morphological changes and cell cycle distribution. qRT-PCR was utilized to measure miRNA and mRNA expression levels, while a dual luciferase reporter assay validated the interaction between miR-199a-5p and E2F3.
RESULTS: Euxanthone significantly (P < 0.05) inhibited cell proliferation in all HCC cell lines, with IC50 values between 6.25 and 25 μM. HepG2 cells exhibited pronounced sensitivity, with an IC50 of 6.25 μM. Euxanthone induced a G1 phase arrest, characterized by decreased expression of Cyclin D1 and E, and increased levels of p21. Additionally, it upregulated miR-199a-5p, which was identified as a mediator of the antiproliferative effects by targeting E2F3. Euxanthone treatment also significantly (P < 0.05) inhibited HepG2 cell migration in a wound healing assay.
DISCUSSION: The findings demonstrate that euxanthone exerts its anticancer activity in HCC cells by modulating the miR-199a-5p/E2F3 axis, leading to G1 arrest and inhibition of migration. These results align with prior studies on natural compounds as modulators of oncogenic signaling pathways and highlight miR-199a-5p as a crucial mediator for anticancer effects of euxanthone. The low toxicity toward normal liver cells further emphasizes its therapeutic potential.
CONCLUSION: Taken together, euxanthone exerts antiproliferative effects on HCC cells via the miR-199a-5p-E2F3 axis and inhibits cell migration. These findings support its potential as a therapeutic agent for HCC, highlighting the need for further investigation into its clinical applications.
METHODS: HCC cell lines (HepG2, Huh-7, SNU-398, SK-HEP-1, Hep3B) and the normal liver cell line THLE-2 were cultured and treated with euxanthone at concentrations between 0 and 100 μM. Cell viability was evaluated using the MTT assay, while phase contrast microscopy and cell cycle analysis were performed to evaluate morphological changes and cell cycle distribution. qRT-PCR was utilized to measure miRNA and mRNA expression levels, while a dual luciferase reporter assay validated the interaction between miR-199a-5p and E2F3.
RESULTS: Euxanthone significantly (P < 0.05) inhibited cell proliferation in all HCC cell lines, with IC50 values between 6.25 and 25 μM. HepG2 cells exhibited pronounced sensitivity, with an IC50 of 6.25 μM. Euxanthone induced a G1 phase arrest, characterized by decreased expression of Cyclin D1 and E, and increased levels of p21. Additionally, it upregulated miR-199a-5p, which was identified as a mediator of the antiproliferative effects by targeting E2F3. Euxanthone treatment also significantly (P < 0.05) inhibited HepG2 cell migration in a wound healing assay.
DISCUSSION: The findings demonstrate that euxanthone exerts its anticancer activity in HCC cells by modulating the miR-199a-5p/E2F3 axis, leading to G1 arrest and inhibition of migration. These results align with prior studies on natural compounds as modulators of oncogenic signaling pathways and highlight miR-199a-5p as a crucial mediator for anticancer effects of euxanthone. The low toxicity toward normal liver cells further emphasizes its therapeutic potential.
CONCLUSION: Taken together, euxanthone exerts antiproliferative effects on HCC cells via the miR-199a-5p-E2F3 axis and inhibits cell migration. These findings support its potential as a therapeutic agent for HCC, highlighting the need for further investigation into its clinical applications.